Website & contact details
- Website
Nonacus Limited
- Incorporated
- 14 May 2015 (11 years)
- Industry
- Research and experimental development on biotechnology (72110)
- Owned by
- Accounts type
- Audit exemption subsidiary
- Region
- West Midlands
- Address
- Unit 5 Quinton Business Park 11 RidgewayQuintonBirminghamB32 1AF
Filing status
- Accounts due
- 30 September 2027
- Last accounts
- 31 December 2025
- Conf. stmt due
- 23 July 2027
- Last conf. stmt
- 9 July 2026
Charges
- Total
- 1
- Outstanding
- 1
- Part satisfied
- 0
- Satisfied
- 0
Officers 4 active
Officer details are public data from the Companies House register.
British
Born April 1986 (40)
Director · Appointed 24 March 2016
Also at Bugs Bioscience Limited · more companies
British
Born August 1963 (63)
British
Born January 1977 (49)
British
Born September 1982 (44)
Officer history (2 former)
5 May 2026
6 June 2023
Resigned Garnett, Kay as Secretary
1 August 2019
Resigned Sale, Christopher David as Secretary
31 July 2019
Appointed Garnett, Kay as Secretary
24 March 2016
9 March 2016
Appointed Sale, Christopher David as Secretary
14 May 2015
14 May 2015
Ownership 1 active
People and entities with significant control, from the Companies House PSC register
Corporate entity · Notified 27 June 2023
Owns 75–100% of shares
Holds 75–100% of voting rights
Right to appoint and remove directors
Private Limited Company
Reg. no. 13082367
Former controllers (3)
27 June 2023
27 June 2023
27 June 2023
Group structure 3 companies
Ownership group derived from the Companies House PSC register
Nonacus Limited This company Owns 75–100% of shares
Prenata Limited Owns 25–50% of shares
Financials
Figures from 2021 accounts. Newer accounts, made up to 31 December 2025, are filed but not read yet. See them on Companies House
- Net Assets
- £25,186,089
- up £22,851,416 (979%)
- 2020: £2,334,673 in the 2021 accounts
- Cash
- £30,620,747
- up £28,646,281 (1451%)
- Turnover
- £53,878,697
- up £47,193,691 (706%)
- Profit Before Tax
- £33,924,092
- up £31,845,681 (1532%)
- Employees
- 48
- up 35 (269%)
- Debt Ratio
- 34%
- Current Ratio
- 2.9x
- Profit Margin
- 63%
- Return on Equity
- 109%
Trend
Net Assets
Balance sheet detail
| 2021 | 2020 | 2019 | |
|---|---|---|---|
| Fixed Assets | £2,896,150 | £840,208 | £104,632 |
| Current Assets | £35,014,408 | £3,530,891 | £413,419 |
| Debtors | £3,408,210 | £1,318,669 | |
| Cash | £30,620,747 | £1,974,466 | |
| Creditors (< 1 year) | £12,174,201 | £1,992,260 | £133,939 |
| Creditors (> 1 year) | £0 | £44,167 | £110,309 |
| Net Current Assets | £22,840,207 | £1,538,631 | £279,480 |
| Net Assets | £25,186,089 | £2,334,672 | £271,339 |
| Shareholder Funds | £25,186,089 | £2,334,672 | £271,339 |
| Turnover | £53,878,697 | ||
| Cost of Sales | £12,590,501 | ||
| Gross Profit | £41,288,196 | ||
| Admin Expenses | £7,364,083 | ||
| Staff Costs | £4,994,583 | ||
| Operating Profit | £33,924,113 | ||
| Profit Before Tax | £33,924,092 | ||
| Tax | £6,572,676 | ||
| Profit for Period | £27,351,416 | £2,063,332 | |
What Nonacus say about themselves
“Helping genomic healthcare professionals and researchers improve patient care through validated liquid biopsy NGS solutions. Click here to learn more.”
Filings
Recent filings only. See the full history on Companies House
| Date | Description | Made Up To | Pages | |
|---|---|---|---|---|
| 1 September 2026 | Accounts filing | |||
| 1 September 2026 | Audit exemption subsidiary accounts | 31 December 2025 | ||
| 23 July 2026 | Other filing | |||
| 23 July 2026 | Other filing | |||
| 16 July 2026 | Confirmation statement with no updates | 9 July 2026 |
Some other companies at this address
Other companies in this industry
Sandwich
Newcastle Upon Tyne
Edinburgh
By trade and location
Explore the largest companies
Need accounts figures, ownership or websites for thousands of companies? Bulk data & API →